During the recent San Antonio Breast Cancer Symposium (SABCS), multiple studies were presented that reinforced the impact of the Oncotype DX breast cancer test on changing treatment decisions across multiple health care systems. Decision impact studies – studies that are designed to determine if using the Oncotype DX breast cancer test would change a doctor’s decision about how to best treat a patient – were conducted in Australia, Germany and the UK. The results of these studies, which included a total of 658 invasive breast cancer patients, confirm data from previous similar studies that the Oncotype DX Recurrence Score® (RS) changes initial treatment decisions by approximately 30% in patients with ER+ early stage breast cancer.
"By providing prognostic and predictive information beyond traditional markers, Oncotype DX gives me and my patients greater confidence in selecting the most appropriate treatment option," said Simon Holt, MA, MB, BChir, FRCS, Lead Breast Surgeon, Hywel Dda NHS Trust Board, Wales, UK. "The results of this study reinforce that the use of Oncotype DX may result in better patient care by enabling physicians to tailor treatment recommendations and by providing added reassurance to patients that they have made the right decision about chemotherapy based on their individual tumor biology."
Additionally, data continues to reconfirm the accuracy, precision, reproducibility and consistency of the Recurrence Score results in patients with early-stage breast cancer. Presentations included ten international studies from the United Kingdom, Germany, France, Ireland, Australia, Venezuela, and a review including data from Israel, Canada, Hungary, Japan, and Singapore.
Christer Svedman, director, medical affairs in Europe, Genomic Health, said during the SABCS meeting, "We are committed to bringing these benefits into clinical practice worldwide."
For more information about the global studies presented at SABCS, click on the following link:
http://investor.genomichealth.com/releasedetail.cfm?ReleaseID=632392